Rubius Therapeutics, Inc. (RUBY)

Market Cap	19.24M
Revenue (ttm)	n/a
Net Income (ttm)	-214.55M
Shares Out	90.36M
EPS (ttm)	-2.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	599,372
Open	0.22
Previous Close	0.213
Day's Range	0.2 - 0.231
52-Week Range	0.2 - 13.52
Beta	2.43
Analysts	Sell
Price Target	10.71 (+5,004.9%)
Earnings Date	Nov 14, 2022

About RUBY

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

• Industry: Biotechnology
• IPO Date: Jul 18, 2018
• CEO: Pablo Cagnoni
• Employees: 9
• Stock Exchange: NASDAQ
• Ticker Symbol: RUBY

Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for RUBY stock is "Sell." The 12-month stock price forecast is 10.71, which is an increase of 5,004.86% from the latest price.

Price Target

$10.71

(5,004.86% upside)

Analyst Consensus: Sell

Stock Forecasts